CY2039B1 - 5-HT 1-like receptor agonist for rectal administration - Google Patents

5-HT 1-like receptor agonist for rectal administration

Info

Publication number
CY2039B1
CY2039B1 CY9802039A CY9802039A CY2039B1 CY 2039 B1 CY2039 B1 CY 2039B1 CY 9802039 A CY9802039 A CY 9802039A CY 9802039 A CY9802039 A CY 9802039A CY 2039 B1 CY2039 B1 CY 2039B1
Authority
CY
Cyprus
Prior art keywords
pct
receptor agonist
rectal administration
sec
date
Prior art date
Application number
CY9802039A
Other languages
English (en)
Original Assignee
Glaxo Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Sa filed Critical Glaxo Lab Sa
Publication of CY2039B1 publication Critical patent/CY2039B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY9802039A 1992-05-07 1998-04-30 5-HT 1-like receptor agonist for rectal administration CY2039B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929209882A GB9209882D0 (en) 1992-05-07 1992-05-07 Compositions

Publications (1)

Publication Number Publication Date
CY2039B1 true CY2039B1 (en) 1998-04-30

Family

ID=10715158

Family Applications (1)

Application Number Title Priority Date Filing Date
CY9802039A CY2039B1 (en) 1992-05-07 1998-04-30 5-HT 1-like receptor agonist for rectal administration

Country Status (33)

Country Link
US (1) US5705506A (cs)
EP (1) EP0639072B1 (cs)
JP (1) JPH07506570A (cs)
KR (1) KR100253111B1 (cs)
AT (1) ATE163850T1 (cs)
AU (1) AU670083B2 (cs)
BE (1) BE1007024A5 (cs)
BG (1) BG62120B1 (cs)
BR (1) BR1100108A (cs)
CA (1) CA2135179C (cs)
CH (1) CH685920A5 (cs)
CY (1) CY2039B1 (cs)
CZ (1) CZ283512B6 (cs)
DE (1) DE69317418T2 (cs)
ES (1) ES2113533T3 (cs)
FR (1) FR2690847B1 (cs)
GB (2) GB9209882D0 (cs)
GR (1) GR3026584T3 (cs)
HK (1) HK95697A (cs)
HU (2) HU227338B1 (cs)
IE (1) IE75203B1 (cs)
IL (1) IL105468A (cs)
IT (1) IT1261471B (cs)
NO (1) NO306700B1 (cs)
NZ (1) NZ252132A (cs)
OA (1) OA10109A (cs)
RO (1) RO112993B1 (cs)
RU (1) RU2118527C1 (cs)
SG (1) SG46649A1 (cs)
TW (1) TW231970B (cs)
UA (1) UA37206C2 (cs)
WO (1) WO1993021916A1 (cs)
ZA (1) ZA933178B (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044062A1 (en) * 1996-05-23 1997-11-27 Alcon Laboratories, Inc. The use of 5-ht1b/1d agonists to treat ocular pain
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
TW570814B (en) * 1998-03-26 2004-01-11 Fujisawa Pharmaceutical Co Sustained-release pharmaceutical composition
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
AR056690A1 (es) * 2005-10-14 2007-10-17 Athersys Inc Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
EP2627328B1 (en) 2010-10-15 2016-09-14 Contera Pharma APS Combinations of serotonin receptor agonists for treatment of movement disorders
CA2870123C (en) 2012-04-18 2021-02-23 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2082175B (en) * 1980-08-12 1984-05-02 Glaxo Group Ltd Heterocyclic compounds
AU550010B2 (en) * 1980-08-12 1986-02-27 Glaxo Group Limited 5-tryptaminoacetamides, carbamates and ureas
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
GR79215B (cs) * 1982-06-07 1984-10-22 Glaxo Group Ltd
HU196752B (en) * 1983-12-06 1989-01-30 Glaxo Group Ltd Process for production of medical compositions containing indole-derivatives and these compounds
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
SE8505715L (sv) * 1984-12-04 1986-06-05 Glaxo Group Ltd Indolderivat
GB8431426D0 (en) * 1984-12-13 1985-01-23 Glaxo Group Ltd Chemical compounds
US4833153A (en) * 1985-11-08 1989-05-23 Glaxo Group Limited Indole derivatives
NO174052C (no) * 1987-08-13 1994-03-09 Glaxo Group Ltd Analogifremgangsmåte for fremstilling av terapeutisk aktive indolderivater
KR100215627B1 (ko) * 1990-06-07 1999-08-16 레슬리 제인 에드워즈 치료용 헤테로사이클 화합물

Also Published As

Publication number Publication date
FR2690847A1 (fr) 1993-11-12
HU227338B1 (en) 2011-04-28
ATE163850T1 (de) 1998-03-15
DE69317418D1 (de) 1998-04-16
JPH07506570A (ja) 1995-07-20
RU2118527C1 (ru) 1998-09-10
IL105468A (en) 1998-09-24
BG62120B1 (bg) 1999-03-31
HK95697A (en) 1997-08-08
ZA933178B (en) 1994-01-10
NO306700B1 (no) 1999-12-13
OA10109A (en) 1996-12-18
FR2690847B1 (fr) 1995-06-09
GB9209882D0 (en) 1992-06-24
IL105468A0 (en) 1993-08-18
SG46649A1 (en) 1998-02-20
CZ272394A3 (en) 1995-10-18
BE1007024A5 (fr) 1995-02-21
US5705506A (en) 1998-01-06
GR3026584T3 (en) 1998-07-31
ITRM930286A1 (it) 1994-11-06
DE69317418T2 (de) 1998-07-30
IT1261471B (it) 1996-05-23
UA37206C2 (uk) 2001-05-15
ITRM930286A0 (it) 1993-05-06
WO1993021916A1 (en) 1993-11-11
IE930339A1 (en) 1993-11-17
HUT71418A (en) 1995-11-28
BR1100108A (pt) 1999-12-07
CH685920A5 (fr) 1995-11-15
EP0639072B1 (en) 1998-03-11
GB2266665A (en) 1993-11-10
IE75203B1 (en) 1997-08-27
HU211638A9 (en) 1995-12-28
EP0639072A1 (en) 1995-02-22
TW231970B (cs) 1994-10-11
GB9309209D0 (en) 1993-06-16
RO112993B1 (ro) 1998-03-30
NO944214L (no) 1994-11-07
BG99167A (bg) 1995-06-30
AU4064093A (en) 1993-11-29
AU670083B2 (en) 1996-07-04
CA2135179C (en) 2000-12-05
NZ252132A (en) 1996-09-25
NO944214D0 (no) 1994-11-04
CA2135179A1 (en) 1993-11-11
GB2266665B (en) 1996-05-22
KR100253111B1 (en) 2000-07-01
ES2113533T3 (es) 1998-05-01
CZ283512B6 (cs) 1998-04-15

Similar Documents

Publication Publication Date Title
MX9702865A (es) Agentes estrogenicos.
EP0903349A3 (en) CCR-3 receptor antagonists
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
ZA971279B (en) Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors
EA200000299A1 (ru) Лекарства
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
AU5879299A (en) Adenine derivatives
CY2039B1 (en) 5-HT 1-like receptor agonist for rectal administration
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
UA66861C2 (uk) 2-феніл-1-[4-(2-аміноетокси)бензил]індол в комбінації з естрогенами, способи лікування та продукт для лікування
MXPA03000548A (es) Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
GR3030919T3 (en) Selective system scan for multizone radiotelephone subscriber units.
GR3022615T3 (en) Pharmaceutical compositions based on ebastime or analogues thereof.
WO2000000198A8 (en) Piperidine derivatives having effects on serotonin related systems
NZ331683A (en) New indole and indazole compounds, a process for their preparation and pharmaceutical compositions containing them
GR3036195T3 (en) Novel compounds
MY107354A (en) Substituted cyclohexenes as central nervous system agents
FR2724933B1 (cs)
BG102229A (en) Endothelium receptor antagonists
MY118946A (en) Novel intermediates and their use to prepare n, n''- bridged bisindolylmaleimides
GR3026346T3 (en) Pharmaceutical compositions comprising contignasterol compounds.
UA30798A (uk) Спосіб пролонгованої терапії онкологічних хворих
ES2141671A1 (es) Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.